These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9645341)

  • 21. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
    Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
    Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prognostic factors in non-Hodgkin's lymphomas].
    Mayáns J; Sanz G; Monzó E; Sancho-Tello R; Carrera MD; Figueres J; Sanz MA
    Rev Clin Esp; 1987 May; 180(8):420-5. PubMed ID: 3616025
    [No Abstract]   [Full Text] [Related]  

  • 23. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia.
    De Rossi G; Marroni P; Paganuzzi M; Mauro FR; Tenca C; Zarcone D; Velardi A; Molica S; Grossi CE
    Leukemia; 1997 Jan; 11(1):134-41. PubMed ID: 9001429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54).
    Horst E; Meijer CJ; Radaszkiewicz T; Ossekoppele GJ; Van Krieken JH; Pals ST
    Leukemia; 1990 Aug; 4(8):595-9. PubMed ID: 1974938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.
    He E; Xu XH; Guan H; Chen Y; Chen ZH; Pan ZL; Tang LL; Hu GZ; Li Y; Zhang M; Zhou J; Eriksson S; Fornander T; Skog S
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):352-8. PubMed ID: 20544519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of serum lactic dehydrogenase in non-Hodgkin's lymphoma.
    Hagberg H; Siegbahn A
    Scand J Haematol; 1983 Jul; 31(1):49-56. PubMed ID: 6867608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
    Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
    J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic significance of the histological classification and staging for patients with a malignant non-Hodgkin lymphoma].
    Raemaekers JM; Snoeijen JJ; Bogman MJ; Rutten E; Strijk SP; Manni JJ
    Ned Tijdschr Geneeskd; 1993 Apr; 137(16):815-20. PubMed ID: 8487885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
    Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
    Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.
    Salven P; Teerenhovi L; Joensuu H
    Blood; 1999 Nov; 94(10):3334-9. PubMed ID: 10552942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peripheral blood involvement in non-Hodgkin's lymphoma detected by clonal gene rearrangement as a biological prognostic marker.
    Hiorns LR; Nicholls J; Sloane JP; Horwich A; Ashley S; Brada M
    Br J Cancer; 1994 Feb; 69(2):347-51. PubMed ID: 8297733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin's lymphoma.
    Pérez-Encinas M; Villamayor M; Campos A; González S; Bello JL
    Haematologica; 1998 Aug; 83(8):752-4. PubMed ID: 9793264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma.
    Khalifa KA; Alkilani AA; Ismail H; Soliman MA
    J Egypt Natl Canc Inst; 2008 Mar; 20(1):47-54. PubMed ID: 19847281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
    Jo SA; Hwang SH; Chang CL; Kim SY; Shin HJ; Chung JS; Sol MY; Lee EY
    Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
    Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
    Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.
    Gronowitz JS; Hagberg H; Källander CF; Simonsson B
    Br J Cancer; 1983 Apr; 47(4):487-95. PubMed ID: 6849793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
    Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
    Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
    Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
    Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers.
    Christiansen I; Gidlof C; Kälkner K M; Hagberg H; Bennmarker H; Tötterman T
    Br J Haematol; 1996 Mar; 92(3):639-46. PubMed ID: 8616029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.